echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene's PD-1 new indication is clinically approved

    BeiGene's PD-1 new indication is clinically approved

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On August 17, the official website of CDE showed that BeiGene's tislelizumab (trade name: Beizian) injection was approved by the Food and Drug Administration for the treatment of advanced malignant solid tumors

    Tilelizumab (trade name: Baizean) is a humanized lgG4 anti-programmed death receptor 1 (PD-1) monoclonal antibody, designed to minimize Fcγ in macrophages Receptor binding

    At present, Bizeran has been approved for 5 indications in China

    On January 12, 2021, BeiGene and Novartis reached a cooperation and licensing agreement to develop, Production and commercialization of the anti-PD-1 antibody Bezean (Tilelizumab), with a total transaction value of up to 2.

    On August 6, 2021, BeiGene announced its financial results for the second quarter and the first half of 2021.

    In the first half of 2021, BeiGene's total revenue was 4.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.